02297 RAINMED-B
- 0.265
- 0.0000.00%
RAINMED-B News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Runmed-B (02297.HK) was increased by 300,000 shares by Chairman and Executive Director Huo Yunfei
Glonghui, May 3, 丨 According to the latest equity disclosure data of the Stock Exchange, on April 29, 2024, Runmed-B (02297.HK) was increased by 300,000 shares by Chairman of the Board of Directors and Executive Director Huo Yunfei at an average price of HK$0.14 per share on the market, involving approximately HK$42,000. After the increase in holdings, Huo Yunfei's latest shareholding was 218,733,000 shares, and the shareholding ratio increased from 18.70% to 18.73%.
潤邁德-B：二零二三年年度報告
Rainmed-B (02297) announces 2023 annual results. Shareholders' share loss of 116 million yuan narrowed by 91.4% year-on-year
Rainmed-B (02297) announced its results for the year ended December 31, 2023, and the group achieved acceptance during the period...
RAINMED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Rainmed-B (02297.HK) plans to hold a board meeting on March 28 to consider and approve annual results
Glonghui, March 8 | Runmed-B (02297.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and publication of the Company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any), and to deal with other matters.
RAINMED-B: Date of Board Meeting
Runmed-B (02297) fell 2.90% to 0.242 yuan, hitting a 52-week low
As of 15:11, Runmed-B (02297) is down 2.90% from yesterday's closing price and is now reporting a 52-week low of $0.242; the trading volume is 0.4 million shares, with a turnover of HK$0.10 million.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Runmed-B (02297.HK) received 263,000 shares from Chairman of the Board and Executive Director Huo Yunfei
Glonghui, January 2 | According to the Stock Exchange's latest equity disclosure data, on December 28, 2023, Runmed-B (02297.HK) received 263,000 shares from Chairman of the Board of Directors and Executive Director Huo Yunfei on the market at an average price of HK$0.462 per share, involving approximately HK$121,500. After the increase in holdings, Huo Yunfei's latest shareholding was 218,344,000 shares, and the shareholding ratio increased from 18.67% to 18.69%.
Runmeide-B (02297) fell 3.10% and is now reported at $0.470, hitting a 52-week low
As of 11:12, Runmeide-B (02297) fell 3.10% from yesterday's closing price. It is now reported at $0.470, a 52-week low; the turnover volume is 112,000 shares, with a turnover of HK$54,000.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Runmeide-B (02297.HK): PricewaterhouseCoopers re-hired as auditor
Glonghui November 13 | Runmeide-B (02297.HK) announced that PricewaterhouseCoopers (“PricewaterhouseCoopers”) was re-employed as the company auditor for a term of office until the end of the company's next annual general meeting of shareholders, and the company's board of directors was authorized to determine its remuneration for the year ending December 31, 2023. The board of directors announced that PricewaterhouseCoopers has resigned as the company's auditor, effective November 13, 2023.
Renmed-B (02297.HK) was granted an increase of 124,000 shares by Executive Director Huo Yunfei
GLONGHUI, Oct. 25 | According to the latest equity disclosure information from the Stock Exchange, on October 19, 2023, RunMed-B (02297.HK) was granted Executive Director Huo Yunfei an increase of 124,000 shares at an average price of HK$0.63 per share on the market, involving approximately HK$781,000. After the increase in holdings, Huo Yunfei's latest shareholding was 218,011,000 shares, and the shareholding ratio increased from 18.65% to 18.66%.
Renmed-B (02297.HK) was granted an increase of 142,000 shares by Executive Director Huo Yunfei
GLONGHUI, October 5 | According to the latest equity disclosure information from the Stock Exchange, from September 20 to October 3, 2023, RunMed-B (02297.HK) received Executive Director Huo Yunfei's holdings on the market to increase its holdings by a total of 142,000 shares at an average price of HK$0.64-0.67 per share, involving approximately HK$92,300. After the increase in holdings, Huo Yunfei's latest shareholding was 217,887,000 shares, and the shareholding ratio increased from 18.64% to 18.65%.
RunMed (02297.HK): Innovative products in hand and continued to deliver on commercialization results
In the first half of this year, the medical device industry faced a complex external environment. On the one hand, as the impact of the epidemic subsides, social and economic activities are on the right track. Although medical demand has recovered, the overall recovery is still not very prominent. On the other hand, from the perspective of the capital market, both the primary market and the secondary market are relatively deserted. In terms of the primary market, there were 237 financing incidents in the domestic medical device sector in the first half of the year, with a financing amount of 12.3 billion yuan. The overall trend continued to decline, and the average transaction size of a single transaction continued to drop to 73 million yuan, a record low in the past three years. In terms of the secondary market, medical care from 2021
RAINMED-B: Interim Report 2023
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
Analysis
Price Target
No Data
